DSGN Stock — Design Therapeutics Inc.: Cash, EV, Pipeline

Share price

$12.24

Market cap

$766.0M

Cash

$207.4M

Enterprise value

$558.6M

Balance sheet

Cash	$207.4M
Debt	$0.0M
Net cash	$207.4M
Enterprise value	$558.6M
Basic shares	62.6M shares
Fully diluted shares	85.5M shares
Fully diluted market cap	$1,046.0M
Cash per share	$3.31

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DSGN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	DT-168	Phase 2	Fuchs Endothelial Corneal Dystrophy; Fuchs	—
Jan 12 - Feb 23	DT-216P2	Phase 2	Friedreich Ataxia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DT-216P2

Phase 1 · Active Modality: small-molecule gene-targeted chimera (GeneTAC)

Aliases DT-216

Target FXN (frataxin)

Indications

Friedreich ataxia (FA) (Phase 1)

Status note Lead program. Improved formulation of DT-216 enabling more sustained exposure; Phase 1 SAD in healthy volunteers via IV and subcutaneous routes generally well-tolerated.

DT-168

Phase 2 · Active Modality: small-molecule gene-targeted chimera (GeneTAC), ophthalmic solution (eye drop)

Target TCF4 (mutant, expanded CTG repeat)

Indications

Fuchs endothelial corneal dystrophy (FECD) (Phase 2)

Catalysts

— 2027

Status note Phase 2 data now expected 2027 due to delay in anticipated supply of blow-fill-seal eye droppers.

DT-818

Phase 1 · Active Modality: small-molecule gene-targeted chimera (GeneTAC)

Target DMPK (mutant, expanded CTG repeat)

Indications

Myotonic dystrophy type-1 (DM1) (Phase 1)

Catalysts

— 2027

Status note Development candidate declared Q4 2025; dosing of DM1 patients in open-label Phase 1 MAD trial initiated in first half of 2026.

HD GeneTAC program (candidate not yet declared)

Discovery · Active Modality: small-molecule gene-targeted chimera (GeneTAC)

Target HTT (expanded repeat)

Indications

Huntington's disease (HD) (Discovery)

Status note Early-stage research program; additional product candidates to be declared as they progress.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	DT-216P2
Lead indication	Friedreich Ataxia
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06874010	Phase 2	Recruiting	Sponsor	DSGN	—	Friedreich Ataxia	—
NCT07024693	Phase 2	Recruiting	Sponsor	DSGN	—	Fuchs Endothelial Corneal Dystrophy; Fuchs	—
NCT06772870	Phase 1	Not yet recruiting	Sponsor	DSGN	—	Friedreich Ataxia	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Design Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	3,000,000	+1,050,000	1.87%	2026-08-14
Baker Bros. Advisors	2,678,430	+92,452	0.19%	2026-08-14
Frazier Life Sciences	1,809,854	+1,809,854	0.57%	2026-08-14
ADAR1 Capital Management	0	-10,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

DSGN — Design Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders